Allergy and asthma proceedings最新文献

筛选
英文 中文
Integrating innovation and shared decision-making in allergy and immunology practice. 在过敏和免疫学实践中整合创新和共同决策。
IF 2.6 3区 医学
Allergy and asthma proceedings Pub Date : 2024-11-01 DOI: 10.2500/aap.2024.45.240089
Joseph A Bellanti, Russell A Settipane
{"title":"Integrating innovation and shared decision-making in allergy and immunology practice.","authors":"Joseph A Bellanti, Russell A Settipane","doi":"10.2500/aap.2024.45.240089","DOIUrl":"10.2500/aap.2024.45.240089","url":null,"abstract":"","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"395-397"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Operationalizing shared decision making in clinical practice. 在临床实践中落实共同决策。
IF 2.6 3区 医学
Allergy and asthma proceedings Pub Date : 2024-11-01 DOI: 10.2500/aap.2024.45.240048
Marcus S Shaker, Marylee Verdi
{"title":"Operationalizing shared decision making in clinical practice.","authors":"Marcus S Shaker, Marylee Verdi","doi":"10.2500/aap.2024.45.240048","DOIUrl":"10.2500/aap.2024.45.240048","url":null,"abstract":"<p><p>Shared decision-making (SDM) requires a clear-eyed view of evidence certainty, context, and equipoise in clinical care. This paradigm of care builds on the foundational ethical principle of patient autonomy, further leveraging beneficence, nonmaleficence, and justice to provide bespoke care in the appropriate clinical setting. When evidence is carefully evaluated together with acceptability and feasibility, equity, cost-effectiveness, resources, and patient preferences, an individualized assessment of the trade-off between possible benefits and harms can optimize patient management. In the setting of a conditional recommendation, it is appropriate to engage in SDM with patient partners, to the extent each patient is willing and able to engage in the SDM process. Three conversations inform SDM and include team talk, option talk, and decision talk with discussion of the plan of care. During these conversations, clear communication strategies that are specific, measurable, achievable, realistic, time sensitive, and provide assessment of absolute (not just relative) risk are important to provide necessary education to patient partners. Follow-up is key to ensure that decisions lead to effective treatment. Through this process, it is necessary to minimize cognitive overload and promote a minimally disruptive medicine approach. The acronym \"HOW\" promotes a holistic appraisal of evidence in context, open-minded teamwork with patients and families, and willingness to be a listening presence while serving as a partner and guide and appreciating the multidimensional and unique nature of each individual. SDM is and will continue to remain a cornerstone of appropriate medical care in settings of clinical equipoise.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"398-403"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview of secondary immunodeficiency. 继发性免疫缺陷概述。
IF 2.6 3区 医学
Allergy and asthma proceedings Pub Date : 2024-09-01 DOI: 10.2500/aap.2024.45.240063
Katherine E Herman, Katherine L Tuttle
{"title":"Overview of secondary immunodeficiency.","authors":"Katherine E Herman, Katherine L Tuttle","doi":"10.2500/aap.2024.45.240063","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240063","url":null,"abstract":"<p><p>In contrast to inborn errors of immunity (IEI), which are inherited disorders of the immune system that predispose to infections, malignancy, atopy, and immune dysregulation, secondary immunodeficiencies and immune dysregulation states (SID) are acquired impairments in immune cell function and/or regulation, and may be transient, reversible, or permanent. SIDs can derive from a variety of medical comorbidities, including protein-losing conditions, malnutrition, malignancy, certain genetic syndromes, prematurity, and chronic infections. Medications, including immunosuppressive and chemotherapeutic drugs, can have profound effects on immunity and biologic agents used in rheumatology, neurology, and hematology/oncology practice are increasingly common causes of SID. Iatrogenic factors, including surgical procedures (thymectomy, splenectomy) can also contribute to SID. A thorough case history, medication review, and laboratory evaluation are necessary to identify the primary driver and determine proper management of SID. Careful consideration should be given to whether a primary IEI could be contributing to autoimmunity, malignancy, and posttreatment complications (e.g., antibody deficiency). SID management consists of addressing the driving condition and/or removing the offending agent if feasible. If SID is suspected to be permanent, then antibiotic prophylaxis, additional immunization, and immunoglobulin replacement should be considered.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 5","pages":"347-354"},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary antibody deficiencies. 原发性抗体缺乏症。
IF 2.6 3区 医学
Allergy and asthma proceedings Pub Date : 2024-09-01 DOI: 10.2500/aap.2024.45.240052
Ashley T Nguyen, Marcella R Aquino
{"title":"Primary antibody deficiencies.","authors":"Ashley T Nguyen, Marcella R Aquino","doi":"10.2500/aap.2024.45.240052","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240052","url":null,"abstract":"<p><p>Primary antibody deficiencies are characterized by the inability to effectively produce antibodies and may involve defects in B-cell development or maturation. Primary antibody deficiencies can occur at any age, depending on the disease pathology. Certain primary antibody deficiencies affect males and females equally, whereas others affect males more often. Patients typically present with recurrent sinopulmonary and gastrointestinal infections, and some patients can experience an increased risk of opportunistic infections. Multidisciplinary collaboration is important in the management of patients with primary antibody deficiencies because these patients require heightened monitoring for atopic, autoimmune, and malignant comorbidities and complications. The underlying genetic defects associated with many primary antibody deficiencies have been discovered, but, in some diseases, the underlying genetic defect and inheritance are still unknown. The diagnosis of primary antibody deficiencies is often made through the evaluation of immunoglobulin levels, lymphocyte levels, and antibody responses. A definitive diagnosis is obtained through genetic testing, which offers specific management options and may inform future family planning. Treatment varies but generally includes antibiotic prophylaxis, vaccination, and immunoglobulin replacement. Hematopoietic stem cell transplantation is also an option for certain primary antibody deficiencies.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 5","pages":"310-316"},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hematopoietic stem cell transplantation for primary immunodeficiency. 造血干细胞移植治疗原发性免疫缺陷症。
IF 2.6 3区 医学
Allergy and asthma proceedings Pub Date : 2024-09-01 DOI: 10.2500/aap.2024.45.240069
Nouf Alsaati, Alexandra Grier, Elisa Ochfeld, Susan McClory, Jennifer Heimall
{"title":"Hematopoietic stem cell transplantation for primary immunodeficiency.","authors":"Nouf Alsaati, Alexandra Grier, Elisa Ochfeld, Susan McClory, Jennifer Heimall","doi":"10.2500/aap.2024.45.240069","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240069","url":null,"abstract":"<p><p>Primary immunodeficiencies, also commonly called inborn errors of immunity (IEI), are commonly due to developmental or functional defects in peripheral blood cells derived from hematopoietic stem cells. In light of this, for the past 50 years, hematopoietic stem cell transplantation (HSCT) has been used as a definitive therapy for IEI. The fields of both clinical immunology and transplantation medicine have had significant advances. This, in turn, has allowed for both an increasing ability to determine a monogenic etiology for many IEIs and an increasing ability to successfully treat these patients with HSCT. Therefore, it has become more common for the practicing allergist/immunologist to diagnose and manage a broad range of patients with IEI before and after HSCT. This review aims to provide practical guidance for the clinical allergist/immunologist on the basics of HSCT and known outcomes in selected forms of IEI, the importance of pre-HSCT supportive care, and the critical importance of and guidance for life-long immunologic and medical monitoring of these patients.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 5","pages":"371-383"},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunoglobulin therapy for immunodeficiency. 免疫球蛋白治疗免疫缺陷症。
IF 2.6 3区 医学
Allergy and asthma proceedings Pub Date : 2024-09-01 DOI: 10.2500/aap.2024.45.240053
Bridget E Wilson, Catherine M Freeman
{"title":"Immunoglobulin therapy for immunodeficiency.","authors":"Bridget E Wilson, Catherine M Freeman","doi":"10.2500/aap.2024.45.240053","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240053","url":null,"abstract":"<p><p>Immunoglobulin replacement is donor-derived pooled immunoglobulin G, which provides passive immunity to patients with antibody deficiency or dysfunction. It may be administered <i>via</i> either intravenous or subcutaneous routes. Intravenous immunoglobulin is administered at higher doses every 3-4 weeks, whereas most forms of subcutaneous immunoglobulin are administered at lower doses, usually every 1-2 weeks. Benefits and risks, including adverse effects, convenience, and cost vary according to route of administration. Immunoglobulin products also differ in their composition, so patient-specific comorbidities are important to consider when selecting an immunoglobulin product. We discuss adverse effects associated with immunoglobulin therapy, their associated risk factors, treatment, and ways to mitigate these risks. Finally, the laboratory monitoring and vaccination recommendations for patients on immunoglobulin replacement therapy are reviewed.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 5","pages":"364-370"},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunodeficiency: Burden of Illness. 免疫缺陷:疾病负担。
IF 2.6 3区 医学
Allergy and asthma proceedings Pub Date : 2024-09-01 DOI: 10.2500/aap.2024.45.240060
Justin C Hsueh, Andrew T Van Hersh, Wei Zhao
{"title":"Immunodeficiency: Burden of Illness.","authors":"Justin C Hsueh, Andrew T Van Hersh, Wei Zhao","doi":"10.2500/aap.2024.45.240060","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240060","url":null,"abstract":"<p><p>Immunodeficiency disorders pose substantial burdens on the health-care system and the patients affected. Broadly, immunodeficiencies can be divided into primary immunodeficiency disorders (PIDDs) and secondary immunodeficiency disorders. This review will focus on PIDDs. The overall prevalence for PIDDs is estimated to be ∼1-2% of the population but may be underestimated due to underdiagnosis of these conditions. PIDDs affect males slightly more often than females. The mortality rates differ based on the specific condition but can be extremely high if the condition is left undiagnosed or untreated. The most common causes of death are infections, respiratory complications, and cancers (e.g., lymphoma). Comorbidities and complications include infection, chronic lung disease, granulomatous lymphocytic interstitial lung disease, and autoimmune disorders. The disease burden of patients with common variable immunodeficiency (CVID) is estimated to be greater than patients with diabetes mellitus and chronic obstructive pulmonary disease. PIDDs have a serious impact on the quality of life of the patients, including sleep disturbance, anxiety, and social participation as well as other psychosocial burdens associated with these disorders. The financial cost of PIDDs can be substantial, with the cost of untreated CVID estimated to be $111,053 per patient per year. Indirect costs include productivity loss and time lost due to infusion and hospital visits. Secondary immunodeficiency is not fully discussed in this review but likely contributes equally to the burden of overall immunodeficiency disorders. Management of patients with PIDDs should use a comprehensive approach, including medical, nursing, psychiatric, and quality of life, to improve the outcome.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 5","pages":"294-298"},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunodysregulation in immunodeficiency. 免疫缺陷症的免疫调节。
IF 2.6 3区 医学
Allergy and asthma proceedings Pub Date : 2024-09-01 DOI: 10.2500/aap.2024.45.240058
Christopher Chang
{"title":"Immunodysregulation in immunodeficiency.","authors":"Christopher Chang","doi":"10.2500/aap.2024.45.240058","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240058","url":null,"abstract":"<p><p>The primary immunodeficiency diseases are often accompanied by autoimmunity, autoinflammatory, or aberrant lymphoproliferation. The paradoxical nature of this association can be explained by the multiple cells and molecules involved in immune networks that interact with each other in synergistic, redundant, antagonistic, and parallel arrangements. Because progressively more immunodeficiencies are found to have a genetic etiology, in many cases, a monogenic pathology, an understanding of why immunodeficiency is really an immune dysfunction becomes evident. Understanding the role of specific genes allows us to better understand the complete nature of the inborn error of immunity (IEI); the latter is a term generally used when a clear genetic etiology can be discerned. Autoimmune cytopenias, inflammatory bowel disease, autoimmune thyroiditis, and autoimmune liver diseases as well as lymphomas and cancers frequently accompany primary immunodeficiencies, and it is important that the practitioner be aware of this association and to expect that this is more common than not. The treatment of autoimmune or immunodysregulation in primary immunodeficiencies often involves further immunosuppression, which places the patient at even greater risk of infection. Mitigating measures to prevent such an infection should be considered as part of the treatment regimen. Treatment of immunodysregulation should be mechanism based, as much as we understand the pathways that lead to the dysfunction. Focusing on abnormalities in specific cells or molecules, <i>e.g.,</i> cytokines, will become increasingly used to provide a targeted approach to therapy, a prelude to the success of personalized medicine in the treatment of IEIs.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 5","pages":"340-346"},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunodeficiency: Complement disorders. 免疫缺陷:补体失调
IF 2.6 3区 医学
Allergy and asthma proceedings Pub Date : 2024-09-01 DOI: 10.2500/aap.2024.45.240050
Jeremy C McMurray, Brandon J Schornack, Andrew L Weskamp, Katherine J Park, Joshua D Pollock, W Grant Day, Aaron T Brockshus, Douglas E Beakes, David J Schwartz, Cecilia P Mikita, Luke M Pittman
{"title":"Immunodeficiency: Complement disorders.","authors":"Jeremy C McMurray, Brandon J Schornack, Andrew L Weskamp, Katherine J Park, Joshua D Pollock, W Grant Day, Aaron T Brockshus, Douglas E Beakes, David J Schwartz, Cecilia P Mikita, Luke M Pittman","doi":"10.2500/aap.2024.45.240050","DOIUrl":"10.2500/aap.2024.45.240050","url":null,"abstract":"<p><p>The complement system is an important component of innate and adaptive immunity that consists of three activation pathways. The classic complement pathway plays a role in humoral immunity, whereas the alternative and lectin pathways augment the innate response. Impairment, deficiency, or overactivation of any of the known 50 complement proteins may lead to increased susceptibility to infection with encapsulated organisms, autoimmunity, hereditary angioedema, or thrombosis, depending on the affected protein. Classic pathway defects result from deficiencies of complement proteins C1q, C1r, C1s, C2, and C4, and typically manifest with features of systemic lupus erythematosus and infections with encapsulated organisms. Alternative pathway defects due to deficiencies of factor B, factor D, and properdin may present with increased susceptibility to Neisseria infections. Lectin pathway defects, including Mannose-binding protein-associated serine protease 2 (MASP2) and ficolin 3, may be asymptomatic or lead to pyogenic infections and autoimmunity. Complement protein C3 is common to all pathways, deficiency of which predisposes patients to severe frequent infections and glomerulonephritis. Deficiencies in factor H and factor I, which regulate the alternative pathway, may lead to hemolytic uremic syndrome. Disseminated Neisseria infections result from terminal pathway defects (i.e., C5, C6, C7, C8, and C9). Diagnosis of complement deficiencies involves screening with functional assays (i.e., total complement activity [CH50], alternative complement pathway activity [AH50], enzyme-linked immunosorbent assay [ELISA]) followed by measurement of individual complement factors by immunoassay. Management of complement deficiencies requires a comprehensive and individualized approach with special attention to vaccination against encapsulated bacteria, consideration of prophylactic antibiotics, treatment of comorbid autoimmunity, and close surveillance.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 5","pages":"305-309"},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11441536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical features, severity, and immunological changes during venom immunotherapy in children and adults. 儿童和成人接受毒液免疫疗法时的临床特征、严重程度和免疫学变化。
IF 2.6 3区 医学
Allergy and asthma proceedings Pub Date : 2024-07-01 DOI: 10.2500/aap.2024.45.240017
Betul Buyuktiryaki, Francesko Hela, Ayse Bilge Ozturk, Adile Berna Dursun, Halil Donmez, Asli Gelincik, Osman Ozan Yegit, Suleyman Tolga Yavuz, Umit Murat Sahiner, Ozgur Albayrak, Ebru Damadoglu, Tuba Erdogan, Sinem Firtina, Dilber Taylan, Ozge Soyer, Gul Karakaya, Ali Fuat Kalyoncu, Bulent Sekerel, Cansin Sackesen
{"title":"Clinical features, severity, and immunological changes during venom immunotherapy in children and adults.","authors":"Betul Buyuktiryaki, Francesko Hela, Ayse Bilge Ozturk, Adile Berna Dursun, Halil Donmez, Asli Gelincik, Osman Ozan Yegit, Suleyman Tolga Yavuz, Umit Murat Sahiner, Ozgur Albayrak, Ebru Damadoglu, Tuba Erdogan, Sinem Firtina, Dilber Taylan, Ozge Soyer, Gul Karakaya, Ali Fuat Kalyoncu, Bulent Sekerel, Cansin Sackesen","doi":"10.2500/aap.2024.45.240017","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240017","url":null,"abstract":"<p><p><b>Background:</b> Hymenoptera venom allergy (HVA) is among the most common causes of severe allergic reactions worldwide. <b>Objective:</b> To investigate clinical features and factors that affect the severity of HVA and to determine the alterations in immunologic biomarkers after venom immunotherapy (VIT). <b>Methods:</b> Seventy-six adults and 36 children were prospectively investigated. We analyzed specific immunoglobulin E (sIgE) and sIgG4 levels of venom extracts and components (rApi m1, rApi m10, rVes v1, rVes v5, rPol d5) before and after the first year of VIT. <b>Results:</b> Although cardiovascular symptoms were more common in adults (p < 0.001), the skin was the most affected organ in children (p = 0.009). Serum basal tryptase (sBT) levels were higher in the adults than the children (p < 0.001). The absence of urticaria (odds ratio [OR] 4.208 [95% confidence interval {CI}, 1.395-12.688]; p = 0.011) and sBT ≥ 5.2 ng/mL (OR 11.941 [95% CI, 5.220-39.733]; p < 0.001) were found as the risk factors for grade IV reactions. During VIT, changes in sIgE levels were variable. In the Apis VIT group, we observed remarkable increases in sIgG4 levels in Apis extract and rApi m1 but not in Api m10. Vespula extract, rVes v1, and rVes v5 sIgG4 levels were significantly increased in Vespula VIT group, we also detected significant increases in the Polistes extract and rPol d5 sIgG4 levels, which were not observed in the Apis VIT group. In the patients who received both Apis and Vespula VIT, increases in sIgG4 levels were observed for both venoms. <b>Conclusion:</b> Adults and children can have different clinical patterns. After 1 year, VIT induced a strong IgG4 response. Although Apis immunotherapy (IT) induced Apis sIgG4, excluding Api m10, Vespula IT induced both Vespula and Polistes sIgG4.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 4","pages":"276-283"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信